<DOC>
	<DOCNO>NCT00418665</DOCNO>
	<brief_summary>This dose schedule find study AMG 531 design ass activity AMG 531 reduce rate clinically significant bleed blood transfusion subject myelodysplastic syndrome ( MDS ) receive lenalidomide . Subjects MDS plan receive least four cycle lenalidomide treatment disease appropriate screen study . All subject meet eligibility criterion receive lenalidomide 10 mg capsule mouth daily every day 28-day cycle . Subjects receive AMG 531 placebo week subcutaneous injection 16 week .</brief_summary>
	<brief_title>A Safety Efficacy Study Evaluate AMG 531 Treatment Subject With Myelodysplastic Syndrome Receiving Revlimid</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Diagnosis MDS bone marrow biopsy base World Health Organization ( WHO ) classification Low Intermediate1 risk category MDS use IPSS Planned receive lenalidomide 10 mg capsule mouth daily 28 day cycle least 4 cycle Eastern Cooperative Oncology ( ECOG ) performance status 02 Subjects must least 18 year age old Prior exposure &gt; 3 cycle lenalidomide Exposure lenalidomide within last 30 day Prior history leukemia aplastic anemia Prior history stem cell transplantation Prior malignancy ( situ cervical cancer basal cell cancer skin ) unless treat curative intent without evidence disease 3 year randomization Active uncontrolled infection Unstable angina , congestive heart failure [ NYHA &gt; class II ] , uncontrolled hypertension [ diastolic &gt; 100 mmHg ] , uncontrolled cardiac arrhythmia , recent ( within 1 year ) myocardial infarction History arterial thrombosis ( eg , stroke transient ischemic attack ) past year History venous thrombosis past year Received IL11 within 4 week screen Less 4 week since receipt investigational drug device Have previously receive thrombopoietic growth factor Pregnant breast feeding Subjects reproductive potential use adequate contraceptive precaution , judgment investigator Known hypersensitivity recombinant E coliderived product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Revlimid</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Low Platelet Count</keyword>
	<keyword>Low Risk Myelodysplastic Syndrome</keyword>
	<keyword>Intermediate 1 Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
</DOC>